In last trading session, Seres Therapeutics Inc (NASDAQ:MCRB) saw 1.64 million shares changing hands with its beta currently measuring 2.05. Company’s recent per share price level of $0.76 trading at -$0.05 or -6.98% at ring of the bell on the day assigns it a market valuation of $128.54M. That closing price of MCRB’s stock is at a discount of -169.74% from its 52-week high price of $2.05 and is indicating a premium of 28.95% from its 52-week low price of $0.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.33 million shares which gives us an average trading volume of 3.77 million if we extend that period to 3-months.

For Seres Therapeutics Inc (MCRB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.25. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.24 in the current quarter.

Seres Therapeutics Inc (NASDAQ:MCRB) trade information

Upright in the red during last session for losing -6.98%, in the last five days MCRB remained trading in the red while hitting it’s week-highest on Monday, 11/04/24 when the stock touched $0.76 price level, adding 10.4% to its value on the day. Seres Therapeutics Inc’s shares saw a change of -46.06% in year-to-date performance and have moved -3.53% in past 5-day. Seres Therapeutics Inc (NASDAQ:MCRB) showed a performance of -2.09% in past 30-days. Number of shares sold short was 18.05 million shares which calculate 3.48 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 1.25 to the stock, which implies a rise of 39.2% to its current value. Analysts have been projecting 1.25 as a low price target for the stock while placing it at a high target of 1.25. It follows that stock’s current price would drop -64.47% in reaching the projected high whereas dropping to the targeted low would mean a loss of -64.47% for stock’s current value.

Seres Therapeutics Inc (MCRB) estimates and forecasts

Statistics highlight that Seres Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 0.77% of value to its shares in past 6 months, showing an annual growth rate of -3.37% while that of industry is 17.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -96.50% from the last financial year’s standing.

Company posted 1.87M and 64k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.22% during past 5 years.

Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders

Insiders are in possession of 13.23% of company’s total shares while institution are holding 41.26 percent of that, with stock having share float percentage of 47.55%. Investors also watch the number of corporate investors in a company very closely, which is 41.26% institutions for Seres Therapeutics Inc that are currently holding shares of the company. FLAGSHIP PIONEERING INC. is the top institutional holder at MCRB for having 23.12 million shares of worth $16.73 million. And as of 2024-06-30, it was holding 15.8226 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 22.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.5489 of outstanding shares, having a total worth of $16.44 million.